perhexiline has been researched along with Heart Failure in 21 studies
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine whether short-term treatment with perhexiline improves cardiac energetics, left ventricular function, and symptoms of heart failure by altering cardiac substrate utilization." | 9.20 | Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. ( Abozguia, K; Beadle, RM; Bowater, S; Frenneaux, MP; Horowitz, J; Kuehl, M; Leyva, F; Thies, F; Wagenmakers, AJ; Williams, LK; Yousef, Z, 2015) |
| " In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome." | 9.19 | Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. ( Beadle, R; Brindley, G; Bruce, M; Cameron, D; Dawson, D; Frenneaux, M; Jagpal, B; Lang, C; Mckiddie, F; Nightingale, P; Rudd, A; Schwarz, K; Singh, S, 2014) |
| "The re-purposing of the anti-anginal drug perhexiline (PHX) has resulted in symptomatic improvements in heart failure (HF) patients." | 8.93 | Pleiotropic mechanisms of action of perhexiline in heart failure. ( Bannister, ML; George, CH; Mitchell, AN; Preece, R; Yousef, Z, 2016) |
| "Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise." | 6.71 | Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. ( Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005) |
| "The aim of this study was to determine whether short-term treatment with perhexiline improves cardiac energetics, left ventricular function, and symptoms of heart failure by altering cardiac substrate utilization." | 5.20 | Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. ( Abozguia, K; Beadle, RM; Bowater, S; Frenneaux, MP; Horowitz, J; Kuehl, M; Leyva, F; Thies, F; Wagenmakers, AJ; Williams, LK; Yousef, Z, 2015) |
| " In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome." | 5.19 | Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. ( Beadle, R; Brindley, G; Bruce, M; Cameron, D; Dawson, D; Frenneaux, M; Jagpal, B; Lang, C; Mckiddie, F; Nightingale, P; Rudd, A; Schwarz, K; Singh, S, 2014) |
| "The re-purposing of the anti-anginal drug perhexiline (PHX) has resulted in symptomatic improvements in heart failure (HF) patients." | 4.93 | Pleiotropic mechanisms of action of perhexiline in heart failure. ( Bannister, ML; George, CH; Mitchell, AN; Preece, R; Yousef, Z, 2016) |
| "Heart failure is a major cause of morbidity and mortality in society." | 2.76 | Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial. ( Abozguia, K; Beadle, RM; Frenneaux, MP; Leon, FL; Patel, K; Wagenmakers, A; Williams, LK; Yousef, Z, 2011) |
| "Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise." | 2.71 | Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. ( Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005) |
| "Several therapies commonly used for the treatment of acute heart failure syndromes (AHFS) present some well-known limitations and have been associated with an early increase in the risk of death." | 2.44 | Overview of emerging pharmacologic agents for acute heart failure syndromes. ( Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ceccarelli, SM | 1 |
| Chomienne, O | 1 |
| Gubler, M | 1 |
| Arduini, A | 1 |
| Singh, S | 1 |
| Beadle, R | 1 |
| Cameron, D | 1 |
| Rudd, A | 1 |
| Bruce, M | 1 |
| Jagpal, B | 1 |
| Schwarz, K | 1 |
| Brindley, G | 1 |
| Mckiddie, F | 1 |
| Nightingale, P | 1 |
| Lang, C | 1 |
| Dawson, D | 1 |
| Frenneaux, M | 2 |
| Cappola, TP | 1 |
| Beadle, RM | 3 |
| Williams, LK | 2 |
| Kuehl, M | 1 |
| Bowater, S | 1 |
| Abozguia, K | 2 |
| Leyva, F | 1 |
| Yousef, Z | 3 |
| Wagenmakers, AJ | 1 |
| Thies, F | 1 |
| Horowitz, J | 2 |
| Frenneaux, MP | 6 |
| Davogustto, G | 1 |
| Taegtmeyer, H | 1 |
| Loudon, BL | 1 |
| Noordali, H | 1 |
| Gollop, ND | 1 |
| Madhani, M | 1 |
| George, CH | 1 |
| Mitchell, AN | 1 |
| Preece, R | 1 |
| Bannister, ML | 1 |
| Heggermont, WA | 1 |
| Papageorgiou, AP | 1 |
| Heymans, S | 1 |
| van Bilsen, M | 1 |
| Fragasso, G | 1 |
| Salerno, A | 1 |
| Spoladore, R | 1 |
| Bassanelli, G | 1 |
| Arioli, F | 1 |
| Margonato, A | 1 |
| Di Napoli, P | 1 |
| Palaniswamy, C | 1 |
| Mellana, WM | 1 |
| Selvaraj, DR | 1 |
| Mohan, D | 1 |
| Horowitz, JD | 2 |
| Chirkov, YY | 1 |
| Kennedy, JA | 1 |
| Sverdlov, AL | 1 |
| Patel, K | 1 |
| Leon, FL | 1 |
| Wagenmakers, A | 1 |
| Lee, L | 1 |
| Campbell, R | 1 |
| Scheuermann-Freestone, M | 1 |
| Taylor, R | 1 |
| Gunaruwan, P | 1 |
| Williams, L | 2 |
| Ashrafian, H | 3 |
| Fraser, AG | 1 |
| Clarke, K | 1 |
| deGoma, EM | 1 |
| Vagelos, RH | 1 |
| Fowler, MB | 1 |
| Ashley, EA | 1 |
| De Luca, L | 1 |
| Mebazaa, A | 1 |
| Filippatos, G | 1 |
| Parissis, JT | 1 |
| Böhm, M | 1 |
| Voors, AA | 1 |
| Nieminen, M | 1 |
| Zannad, F | 1 |
| Rhodes, A | 1 |
| El-Banayosy, A | 1 |
| Dickstein, K | 1 |
| Gheorghiade, M | 1 |
| Opie, LH | 1 |
| Silver, PJ | 1 |
| Monteforte, PB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF)[NCT00839228] | Phase 2 | 70 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| Metabolic Manipulation in Chronic Heart Failure[NCT00841139] | Phase 2 | 50 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery[NCT00845364] | Phase 2/Phase 3 | 290 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy[NCT00989508] | Phase 2/Phase 3 | 220 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for perhexiline and Heart Failure
| Article | Year |
|---|---|
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm.
Topics: Cardiovascular Agents; Heart Failure; Humans; Nitrites; Perhexiline | 2016 |
Pleiotropic mechanisms of action of perhexiline in heart failure.
Topics: Animals; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Design; Heart Failure; Humans | 2016 |
Metabolic support for the heart: complementary therapy for heart failure?
Topics: Acetyl-CoA C-Acyltransferase; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Di | 2016 |
Metabolic therapy of heart failure.
Topics: Animals; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Fatty Acids, Nonesterified; Heart | 2008 |
Metabolic modulation: a new therapeutic target in treatment of heart failure.
Topics: Acetanilides; Carnitine O-Palmitoyltransferase; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glu | 2011 |
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricula | 2010 |
Emerging therapies for the management of decompensated heart failure: from bench to bedside.
Topics: Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Cardiac Myosins; Cardiotonic A | 2006 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Perhexiline.
Topics: Angina Pectoris; Animals; Aortic Valve Stenosis; Calcium Channel Blockers; Carnitine O-Palmitoyltran | 2007 |
Overview of emerging pharmacologic agents for acute heart failure syndromes.
Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans | 2008 |
4 trials available for perhexiline and Heart Failure
| Article | Year |
|---|---|
Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome.
Topics: Cardiovascular Agents; Clinical Protocols; Double-Blind Method; Heart Failure; Humans; Outcome Asses | 2014 |
Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Cardiovascular Agents; Double-Blind Method; Echocardiography; Energy Metabo | 2015 |
Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial.
Topics: Adenosine Triphosphate; Cardiac Catheterization; Cardiomyopathy, Dilated; Cardiovascular Agents; Dou | 2011 |
Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Topics: Aged; Cardiovascular Agents; Chronic Disease; Echocardiography, Stress; Fatty Acids; Female; Glucose | 2005 |
8 other studies available for perhexiline and Heart Failure
| Article | Year |
|---|---|
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Catalytic Domain; Diabetes Mellitus, Type 2; E | 2011 |
Perhexiline: lessons for heart failure therapeutics.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Humans; Male; Myocardium; Perhexi | 2015 |
Perhexiline, Cardiac Energetics, and Heart Failure: Lessons From the First Law of Thermodynamics.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Humans; Male; Myocardium; Perhexi | 2015 |
Reply: Perhexiline, Cardiac Energetics, and Heart Failure: Lessons From the First Law of Thermodynamics.
Topics: Cardiomyopathy, Dilated; Energy Metabolism; Female; Heart Failure; Humans; Male; Myocardium; Perhexi | 2015 |
The metabolic treatment of coronary artery disease and heart failure.
Topics: Carnitine O-Palmitoyltransferase; Coronary Artery Disease; Epoxy Compounds; Heart Failure; Humans; P | 2009 |
The pathophysiology of heart failure: a tale of two old paradigms revisited.
Topics: Cardiovascular Agents; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Heart Failu | 2008 |
Drugs and the heart. III. Calcium antagonists.
Topics: Angina Pectoris; Aniline Compounds; Arrhythmias, Cardiac; Calcium; Cardiomegaly; Diuretics; Heart Di | 1980 |
Differential effects of pharmacological modulators of cardiac myofibrillar ATPase activity in normal and myopathic (BIO 14.6) hamsters.
Topics: Adenosine Triphosphatases; Animals; Anti-Arrhythmia Agents; Bepridil; Calcium; Calcium Channel Block | 1988 |